The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in noise, tinnitus, and hyperacusis), as well as the advancement of preclinical development for the candidate … Read More
PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be presenting data on its lead program PST-611, expressing human … Read More
September 24, 2024, SPRIM PRO – SPRIM PRO, a CRO renowned for its innovative approach to clinical trials and healthcare, is excited to announce its accepted, peer reviewed publication in Frontiers in Pediatrics medical journal entitled, “Assessment of the reliability … Read More
July 25, 2024 – (PRNewswire) – ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research and care continuum. … Read More
June 18, 2024 – (Forbes Australia) – Founder and CEO Mimi Tang has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen and turn to … Read More
NEW YORK, Oct. 17, 2023 – ObvioHealth, a virtual research organization (VRO) delivering stronger clinical evidence through tech-enabled trials, announces the appointment of John Cassidy as its new Chief Financial Officer and Florence Mowlem as Vice President of Science. The two industry veterans will reinforce the … Read More
LOS ANGELES, July 14, 2023 — Today, Readout AI is announcing it has raised its pre-seed funding. The round, led by Meridian Street Capital, with participation from Mucker Capital, Necessary Ventures, and angel investor Ryan Fukushima (COO of Tempus and CEO of Pathos), … Read More
SINGAPORE, May 26, 2023 – SPRIM Global Investments (SPRIM), a leading health sciences investment firm, completed an equity investment in VCTC Limited, a UK-based specialist clinical trial site. SPRIM funding will enable VCTC to expedite growth through expansion of services and access to … Read More
May 3, 2023 — NEW YORK — ObvioHealth, a pioneering virtual research organization (VRO) announces a partnership with A*STAR’s Singapore Institute for Clinical Sciences (SICS) to identify better and more sensitive ways to measure and capture health outcomes. A*STAR’s SICS aims to identify biomarkers … Read More
NEW YORK, March 16, 2023 /PRNewswire/ — ObvioHealth and Mi-Helper, Inc. announce a partnership to conduct a decentralized clinical trial for a non-invasive neuromodulation device for the treatment of migraines. The randomized controlled trial will be fully remote, enabling data … Read More
LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 301 … Read More
NEW YORK – February 8, 2022 – SPRIM Global Investments announces the promotion of Susan Dallabrida, PhD, to Chief Executive Officer of SPRIM Consultancy. In her nearly 2 years with SPRIM, Susan has brought both scientific and commercial leadership to … Read More
By Susan Dallabrida, PhD The capture of high-quality, accurate and complete datasets in a clinical trial is always of utmost importance. But the stakes could not be higher when it comes to rare disease. It is estimated that there are … Read More
Fibronostics, a global company providing non-invasive, algorithmic diagnostics for NASH patients, announced today that it has secured $8 million in series A funding. The financing round was led by AT Capital, a leading private investment firm in Asia and Elev8.vc, an early-stage deep-tech VC fund. … Read More
Fibronostics, a global diagnostics company, providing non-invasive, algorithmic diagnostics to detect and manage metabolic diseases, announced today Stephen A. Harrison, MD has joined its board of advisors. … Read More
COVID-19 drug development has brought a unique set of clinical challenges, virtual patient training and decentralized trials can be part of the solution. … Read More
PARIS — June 18, 2020 – ObvioHealth, a full-service virtual research organization (VROTM), announces today a partnership with La Foundation Hôpital Paris Saint Joseph to monitor COVID-19 prevalence and symptoms among the oncology patients of the Groupe Hospitalier Paris Saint … Read More
Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million. … Read More
SPRIM and Health Catalyst partner to jumpstart understanding of COVID-19 impact on NASH and NAFLD population to advance clinical trials for liver disease. … Read More
ObvioHealth, a leading virtual health research organization or VRO, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March. … Read More
ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months. … Read More
Learn how social media and digital clinical trials were used for recruiting participants in under-represented racial and ethnic groups. … Read More
Digital clinical trials are conducted in a much different format than that of the traditional “brick and mortar” model. The following infographic will highlight some of the key differences between the two. … Read More
A breakdown of the four practices areas SPRIM utilizes to help its clients meet their commercial endpoints: strategy and innovation, regulatory and scientific affairs, research and clinical services and medical marketing and engagement. … Read More
SPRIM’s portfolio company, ObvioHealth, conducted a double-blind, randomized clinical trial to study the impact of rice vinegar on blood pressure and vascular reactivity. ObvioHealth focused on recruiting minorities, given that high blood pressure disproportionately impacts the black population in the U.S. … Read More
Despite the emergence of the digital age of recruitment, the standard (aged) approaches to recruitment persist: media advertising (television, newspaper advertisements), physician referrals, press releases/public service announcements, posting fliers, physician referrals, random mailings, and cold calls are all still in play. … Read More
“BYOD” or “bring your own device” is the future of clinical studies, and sponsors are embracing what will become the new standard. Subjects using their own devices to fill out diaries and input data is not only less expensive for … Read More
Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States. … Read More
ObvioHealth, meanwhile, has developed an app that enables studies to be run using mobile devices. Data from smart devices such as a Bluetooth blood pressure monitor can integrate with the app, according to the company, which earlier this year raised … Read More
MILO & CLAIMIT View a short, imagined study where ObvioHealth’s Milo demonstrates how digital technology improves patient experience, compliance and data capture using ClaimIt. Follow our fictional subject, Milo, as he uses his mobile phone to participate in a clinical … Read More
The blood brain barrier (BBB) is a system of blood vessels that protects the brain from toxins and chemical fluctuations. While it is necessary to help keep the brain healthy, it also poses a problem in delivering medications that could … Read More
NEW YORK (Reuters Health) – A commercially available formula of Lactobacillus acidophilus and L. casei prevents Clostridium difficile infection and diarrhea during antibiotic treatment, according to a single-center study from China. Although meta-analyses indicate that probiotics decrease antibiotic-associated diarrhea, most … Read More
Lack of diversity within the clinical trial industry poses a grave problem. We cannot assume medicines work similarly across ethnicities. While attracting and retaining minority groups to participate in clinical trials has become a primary focus in the industry, many … Read More
BUSINESSWIRE, 12 February 2018 NEW YORK–(BUSINESS WIRE)–A double-blind, randomized, cross-over study, published in the UK-based, peer-reviewed Nutrition Journal, reported that consumption of milk containing only A2 beta casein protein type (sold in the US as a2 Milk®) reduced acute gastrointestinal … Read More
HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS). Travecta is based on … Read More
PHILADELPHIA–(BUSINESS WIRE)–Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain development. … Read More
ObvioHealth, supported by SPRIM, releases a Mobile App that is positioned to transform clinical studies globally. … Read More
ORLANDO, Fla.–(BUSINESS WIRE)–ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies— the ObvioHealth app. The app removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, … Read More
ObvioHealth, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding. The company is focused on making clinical trials faster and more cost-effective by digitizing the entire process … Read More